
High Q Technologies at Discovery & Development US 2026
October 12–13, 2026
Hilton San Diego Bayfront | San Diego, CA
Drug discovery depends on understanding the complex behavior of biological targets. While traditional approaches provide valuable structural insights, proteins are constantly moving between different conformational states that influence function, binding, and therapeutic potential.
Visit HighQ Technologies at Discovery & Development US 2026 to learn how advanced Electron Paramagnetic Resonance (EPR) spectroscopy helps researchers close the conformation gap by revealing protein dynamics that are often missed by conventional methods.
HighQ's EPR solutions provide insights into conformational changes, molecular interactions, and protein behavior, supporting research in target validation, therapeutic development, and biophysical characterization.
Connect with our team in San Diego to discover how understanding protein dynamics can help accelerate better decisions throughout the drug discovery process.

DEER spectroscopy (double electron-electron resonance) is a pulsed EPR technique that measures the distance between two unpaired electrons, usually spin labels attached to chosen sites on a protein, across a range of roughly 1.5 to 8 nanometers. Because every molecule in the frozen sample contributes to the signal, DEER EPR returns a full distribution of distances instead of a single average, which shows how many conformations a protein adopts and how flexible it is. This article is for protein scientists and drug discovery teams deciding whether DEER fits a project. It covers how the experiment works, how DEER relates to PELDOR, the distance limits, and where DEER is used in drug discovery.

Protein dimerization is one of the most widespread and functionally important forms of protein–protein interaction. Proteins rarely act in isolation in a biological environment; instead, they associate as homodimers, heterodimers or higher-order oligomers to form functional assemblies. This self-assembly occurs in every cellular compartment, from membranes to the nucleus and cytosol, and regulates processes ranging from enzymatic activation and signal transduction to pathogenic pathways. A dimer observed in a crystal structure, however, may represent either a genuine biological assembly or a contact created by crystal packing. A crystal structure provides detailed information about molecular architecture, but it does not by itself establish whether two molecules associate under relevant solution conditions, how strong that interaction is, or whether the subunits retain the same arrangement outside the lattice. Distinguishing between these possibilities is therefore an important task in structural biology, biophysics and pharmaceutical research, where protein–protein interactions can influence function, stability and the binding of potential drug candidates.

Protein dimerization occurs when two protein molecules associate to form a dimer. A crystal structure can reveal how two protein molecules fit together, identifying an interface that may influence protein function or drug discovery. However, a dimer observed in a crystal does not necessarily represent the dominant assembly in solution. Crystal packing can stabilize contacts that are weak, transient, or absent under physiologically relevant conditions. For pharmaceutical researchers, this distinction matters because a proposed dimer interface may form a binding site, regulate protein activity, or provide a target for small molecules. Before using the structure to guide drug design, researchers need to establish whether the protein associates in solution and whether the arrangement of its subunits is consistent with the proposed model.
Ready to see FATHOM in action?
Our applications specialists will walk you through a demo, answer technical questions, and help you assess fit for your specific research program.